By Josh Beckerman 
 

Switzerland-based biotechnology company ADC Therapeutics SA has filed for an initial public offering.

ADC focuses on hematological malignancies and solid tumors.

The company plans to trade on the New York Stock Exchange under symbol ADCT. The filing lists an amount of $150 million.

Auven Therapeutics owns 42.7% stake of ADC. AstraZeneca PLC (AZN) owns 7.1%.

 

Write to Josh Beckerman at josh.beckerman@wsj.com

 

(END) Dow Jones Newswires

September 06, 2019 20:11 ET (00:11 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jun 2020 to Jul 2020 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jul 2019 to Jul 2020 Click Here for more Astrazeneca Charts.